Genentech (DNA) announced that a new study uncovered that fact that its Avastin cancer drug can improve survival among people with severe lung cancer when it is added to other treatments. It is good news for patients, and, one would think, for the company.
Unfortunately, the study also found "showed a lower dose of Avastin was just as good as a higher dose," according to The Wall Street Journal.
The drug makes Genentech a lot of money. The costs is capped at $55,000 a year for approved patients, but the figure is still eye-popping. Avastin sales were $1.7 billion last year.
Genentech’s stock is up over 400% in the last year, so, perhaps goodness is its own reward.
Douglas A. McIntyre can be reached at [email protected]. He does not own securities in companies that he writes about.
It’s Your Money, Your Future—Own It (sponsor)
Retirement can be daunting, but it doesn’t need to be.
Imagine having an expert in your corner to help you with your financial goals. Someone to help you determine if you’re ahead, behind, or right on track. With SmartAsset, that’s not just a dream—it’s reality. This free tool connects you with pre-screened financial advisors who work in your best interests. It’s quick, it’s easy, so take the leap today and start planning smarter!
Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.